This approval confirms that the platform meets Finland’s national requirements for data security, interoperability, and regulatory compliance in the health and social care system.
“Valvira’s approval enables the clinical use of the Hippo Health Platform in Finland. This marks the first step in the platform’s commercialization. We have now launched pilot projects aimed at validating the platform’s impact on healthcare professionals’ workflows. We will share the results of the pilot in October 2025,” confirms Juuso Haavisto, CEO of HippocrAItes.
Hippo Health Platform was approved for Category A1 classification.
For more information and interview requests:
Juuso Haavisto
CEO
juuso.haavisto@hippocraites.fi
tel. +358 50 351 1925
HippocrAItes
Join us at our Future Health event on October 2, 2025, in Meilahti, where we’ll present the pilot results!